Evommune Inc. (EVMN)
EVMN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$5.88
-2.81% on the day
Market cap
$213.4M
Micro cap
Revenue · 2025
$13.0M
+85.7% on 2024
Net income · 2025
-$68.9M
-529.8% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | EVMN on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0002044725 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $13.0M |
| Net income | -$68.9M |
| Operating income | -$81.1M |
| Net margin | -529.8% |
| Operating margin | -623.6% |
| Revenue growth | +85.7% |
| Cash | $44.1M |
| Total assets | $224.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 16.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-09 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-10-01 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 134 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AKBA | Akebia Therapeutics Inc. | $0.7700 | -2.56% | $213.4M |
| CAMP | CAMP4 Therapeutics Corporation | $3.43 | -6.28% | $215.2M |
| ADCT | ADC Therapeutics SA Common Shares | $1.70 | -8.60% | $217.0M |
| MGNX | MacroGenics Inc. | $3.42 | -8.06% | $217.9M |
| PRQR | ProQR Therapeutics N.V. | $1.48 | -8.64% | $208.9M |
| PYXS | Pyxis Oncology Inc. | $1.85 | -7.96% | $221.2M |
| SIGA | SIGA Technologies Inc. | $3.08 | -2.53% | $221.3M |
| KROS | Keros Therapeutics Inc. | $11.23 | -3.27% | $222.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier